Three-day ODAC to review data from confirmatory trials of PD-1/PD-L1 drugs marketed under accelerated approval

FDA will hold a three-day meeting of the Oncologic Drugs Advisory Committee April 27-29 to consider five indications that received accelerated approvals, but that have not been shown to produce a clinical benefit in confirmatory trials.